The BioFINDER Steering Group
Prof Oskar Hansson
Principal Investigator
Professor and Senior Neurologist at the Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University and at the Memory Clinic, Skåne University Hospital. Dr Hansson’s overriding aim is to combine clinical work with innovative research to help patients suffering from neurodegenerative disorders, mainly Alzheimer’s and Parkinson’s diseases. He has funded all his research through significant independent grants from e.g. the European Research Council (ERC) and the Swedish Research Council. His work is widely recognized with papers in e.g. Lancet Neurology and JAMA. His work on biomarkers has influenced the newly proposed diagnostic criteria for Alzheimer’s disease. Dr Hansson is part of and in leading positions in several distinguished scientific networks, including the strategic network in neuroscience at Lund University (MultiPark), Swedish Parkinson Academy, and Swedish Brain Power.
Dr Erik Stomrud
Logistics and clinical assessment
Dr Stomrud is responsible for the logistics of BioFINDER, especially in the cohort with cognitively healthy elderly participants. His overriding research aim is to understand the mechanisms of healthy aging and differentiate it from neurocognitive disorders.
Assoc Prof Sebastian Palmqvist
Clinical assessment and cognitive testing
Dr Palmqvist’s focus lies on the clinical evaluation and follow-up of the patients with mild cognitive symptoms. He is interested in the association between disease mechanisms and clinical symptoms of the patients. Other interests include early biomarkers and cognitive testing. Aside from his research in BioFINDER, dr Palmqvist works clinically at the department of Neurology (Skåne University Hospital, Sweden).
Assoc Prof Niklas Mattsson
Blood and CSF biomarkers
Dr Mattsson’s main research interest is Alzheimer’s disease, where he uses biochemical markers to improve methods for diagnosis and prognosis, inform design of clinical trials, and gain novel understanding of disease mechanisms. He is particularly interested in the importance of different pathological changes during the very early stages of Alzheimer’s disease. He shares his time between research and a neurology residency, and he is also a board-certified specialist in clinical chemistry.
Assoc Prof Ruben Smith
PET
Dr Smith’s main interest is to identify different disease mechanisms using PET to understand the different underlying pathologies of neurocognitive disorders. Since baseline, 18F-Flutemetamol (β-amyloid) has been used within the BioFINDER study, but we are now expanding the number of radiotracers. As January 2017 we are also scanning included patients with 18F-AV-1451 (tau) and 18F-FDG-PET scans. In the upcoming BioFINDER 2 study we will also include 18F-RO6958948 (tau) PET in the scanning protocol and add three high resolution digital GE Discovery MI PET/CT scanners.
A
ssoc Prof Rik Ossenkoppele
PET
Dr. Ossenkoppele uses various neuroimaging techniques (PET: Tau, Aβ, glucose metabolism; MRI: brain atrophy and functional connectivity) to study the Alzheimer’s disease spectrum, with a specific focus on disease heterogeneity, progression and brain resilience. His research is aimed at gaining a better understanding of disease mechanisms Alzheimer’s disease and at optimizing diagnostic and prognostic neuroimaging markers for clinical use. He shares his research time between the Swedish BioFINDER study group and the VUMC Alzheimercenter in Amsterdam.
Assoc Prof Danielle van Westen
MRI
Dr van Westen is a senior neuroradiologist at Skåne University Hospital in Sweden. Her interests include the associations between radiological biomarkers and clinical phenotypes as well as methodological aspects of MRI.
The BioFINDER Study Group and Collaborators
Located in Sweden if not otherwise specified.
Clinical Memory Research Unit, Lund University
Emelie Andersson, PhD student
David Berron, PhD
Alexa Pichet Binette, PhD
Elin Byman, PhD student
Emma Borland, MD PhD student
Anna Callmer, MD
Cecilia Dahl, RN
Eske Gertje, MD PhD student
Isabelle Glans, MD PhD student
Anna-Märta Gustavsson, MD PhD student
Joanna Grzegorska, Administrator
Sara Hall, MD PhD
Oskar Hansson, MD PhD, Head of the research group
Philip Insel, PhD
Shorena Janelidze, PhD
Maurits Johansson, MD
Helena Sletten, MD
Jonas Jester-Broms, MD
Elisabet Londos, MD PhD
Niklas Mattson, MD PhD
Lennart Minthon, MD PhD
Maria Nilsson, PhD
Katarina Nägga, MD PhD
Camilla Orbjörn, MLT
Rik Ossenkoppele, PhD
Sebastian Palmqvist, MD PhD
Marie Persson, RN
Anne-Marie Rohrstock, Administrator
Gemma Salvado Blasco, PhD
Alexander Santillo, MD PhD
Nicola Spotorno, PhD
Erik Stomrud, MD PhD
Anna Svenningsson, MD PhD student
Håkan Toresson, PhD
Olof Strandberg, QMP
Memory Clinic, Ängelholm Hospital
Ida Friberg, RN
Per Johansson, MD PhD
Moa Wibom, MD
Department of Neurology, Skåne University Hospital
Katarina Johansson, RN
Emma Pettersson, RN
Christin Karremo, RN
Ruben Smith, MD PhD
Department of Neurosurgery, Skåne University Hospital
Mattis Jalakas, MD PhD student
MRI unit, Lund University
Linda Knutsson, PhD
Jimmy Lätt, QMP
Peter Mannfolk, PhD
Markus Nilsson, PhD
Freddy Ståhlberg, MD PhD
Pia Sundgren, MD PhD
Danielle van Westen, MD PhD
Clinical Neurochemistry Laboratory, University of Gothenburg
Ulf Andreasson, PhD
Kaj Blennow, MD PhD
Henrik Zetterberg, MD PhD
MRI unit, Karolinska Institutet
Lars-Olof Wahlund, MD PhD
Eric Westman, PhD
Joana Pereira, PhD
PET unit, Lund University
Jonas Jögi, MD PhD
Douglas Hägerström, MD
Tomas Olsson, QMP
Per Wollmer, MD PhD
Developmental and Regenerative Neurobiology, Lund University
Malin Parmar PhD
Ulrich Pfisterer PhD
Other collaborators
GE Healthcare, USA ([18]F-flutemetamol doses for amyloid PET)
AVID/Lilly, USA ([18]F-T807 doses for Tau PET)
Roche, Switzerland ([18]F-RO948 doses for Tau PET)